Search

Displaying results 471 - 480 of 1777 in total
  1. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    [A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.

  2. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … It is administered via intramuscular injection, and requires the establishment of tolerability prior to dosing in treatment-naïve patients [FDA Label].

  3. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    FDA on July 13, 2020. … [L26996] Full FDA approval was granted on August 23, 2021.

  4. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU.

  5. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    In January 2007, the FDA approved the intravenous administration of azacitidine. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

  6. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.

  7. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.

  8. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.

  9. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. … [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.[A39983] This drug is frequently known as _Humira_.

  10. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [L41404] Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers